Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Ornithine transcarbamylase downregulation is associated with poor prognosis in hepatocellular carcinoma.

He L, Cai X, Cheng S, Zhou H, Zhang Z, Ren J, Ren F, Yang Q, Tao N, Chen J.

Oncol Lett. 2019 Jun;17(6):5030-5038. doi: 10.3892/ol.2019.10174. Epub 2019 Mar 21.

2.

A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.

Zhu P, Jin J, Liao Y, Li J, Yu XZ, Liao W, He S.

Oncotarget. 2015 Dec 1;6(38):41383-97. doi: 10.18632/oncotarget.5510.

3.

Clinical and biological significance of transcription termination factor, RNA polymerase I in human liver hepatocellular carcinoma.

Komatsu H, Iguchi T, Ueda M, Nambara S, Saito T, Hirata H, Sakimura S, Takano Y, Uchi R, Shinden Y, Eguchi H, Masuda T, Sugimachi K, Eguchi H, Doki Y, Mori M, Mimori K.

Oncol Rep. 2016 Apr;35(4):2073-80. doi: 10.3892/or.2016.4593. Epub 2016 Jan 25.

PMID:
26821084
4.

Overexpression of WWP1 promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma.

Zhang XF, Chao J, Pan QZ, Pan K, Weng DS, Wang QJ, Zhao JJ, He J, Liu Q, Jiang SS, Chen CL, Zhang HX, Xia JC.

Oncotarget. 2015 Dec 1;6(38):40920-33. doi: 10.18632/oncotarget.5712.

5.

The clinicopathological significance of miR-149 and PARP-2 in hepatocellular carcinoma and their roles in chemo/radiotherapy.

Lin L, Zhang YD, Chen ZY, Chen Y, Ren CP.

Tumour Biol. 2016 Sep;37(9):12339-12346. Epub 2016 Jun 14.

PMID:
27300349
6.

Low expression of DAB2IP contributes to malignant development and poor prognosis in hepatocellular carcinoma.

Zhang X, Li N, Li X, Zhao W, Qiao Y, Liang L, Ding Y.

J Gastroenterol Hepatol. 2012 Jun;27(6):1117-25. doi: 10.1111/j.1440-1746.2011.07049.x.

PMID:
22168621
7.

Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.

Wang G, Chen JH, Qiang Y, Wang DZ, Chen Z.

World J Gastroenterol. 2015 Apr 7;21(13):3983-93. doi: 10.3748/wjg.v21.i13.3983.

8.

Expression and prognostic role of ubiquitination factor E4B in primary hepatocellular carcinoma.

Zhang XF, Pan QZ, Pan K, Weng DS, Wang QJ, Zhao JJ, He J, Liu Q, Wang DD, Jiang SS, Zheng HX, Lv L, Chen CL, Zhang HX, Xia JC.

Mol Carcinog. 2016 Jan;55(1):64-76. doi: 10.1002/mc.22259. Epub 2015 Jan 3.

PMID:
25557723
9.

Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.

Song Y, Pan G, Chen L, Ma S, Zeng T, Man Chan TH, Li L, Lian Q, Chow R, Cai X, Li Y, Li Y, Liu M, Li Y, Zhu Y, Wong N, Yuan YF, Pei D, Guan XY.

Gastroenterology. 2015 Oct;149(4):1068-81.e5. doi: 10.1053/j.gastro.2015.06.010. Epub 2015 Jun 20.

PMID:
26099525
10.

H2.0-like homeobox 1 acts as a tumor suppressor in hepatocellular carcinoma.

Liu T, Chen J, Xiao S, Lei X.

Tumour Biol. 2016 May;37(5):6419-28. doi: 10.1007/s13277-015-4490-z. Epub 2015 Dec 2.

PMID:
26631039
11.

Novel tumor suppressor SPRYD4 inhibits tumor progression in hepatocellular carcinoma by inducing apoptotic cell death.

Zahid KR, Han S, Zhou F, Raza U.

Cell Oncol (Dordr). 2019 Feb;42(1):55-66. doi: 10.1007/s13402-018-0407-3. Epub 2018 Sep 20.

PMID:
30238408
12.
13.

Bromodomain-containing protein 7 (BRD7) as a potential tumor suppressor in hepatocellular carcinoma.

Chen CL, Wang Y, Pan QZ, Tang Y, Wang QJ, Pan K, Huang LX, He J, Zhao JJ, Jiang SS, Zhang XF, Zhang HX, Zhou ZQ, Weng de S, Xia JC.

Oncotarget. 2016 Mar 29;7(13):16248-61. doi: 10.18632/oncotarget.7637.

14.

Identification of PAQR3 as a new candidate tumor suppressor in hepatocellular carcinoma.

Wu HG, Zhang WJ, Ding Q, Peng G, Zou ZW, Liu T, Cao RB, Fei SJ, Li PC, Yang KY, Hu JL, Dai XF, Wu G, Li PD.

Oncol Rep. 2014 Dec;32(6):2687-95. doi: 10.3892/or.2014.3532. Epub 2014 Oct 6.

PMID:
25310770
15.

Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.

Zhang MH, Niu H, Li Z, Huo RT, Wang JM, Liu J.

Cancer Biomark. 2018;23(1):33-43. doi: 10.3233/CBM-181277.

PMID:
29991125
16.

Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients.

Chen D, Chen Y, Yan Y, Pan J, Xing W, Li Q, Zeng W.

BMC Cancer. 2017 Aug 18;17(1):553. doi: 10.1186/s12885-017-3541-9.

17.

Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.

Lu LL, Sun J, Lai JJ, Jiang Y, Bai LH, Zhang LD.

World J Gastroenterol. 2015 Jun 7;21(21):6649-59. doi: 10.3748/wjg.v21.i21.6649.

18.

MicroRNA-608 acts as a prognostic marker and inhibits the cell proliferation in hepatocellular carcinoma by macrophage migration inhibitory factor.

Wang K, Liang Q, Wei L, Zhang W, Zhu P.

Tumour Biol. 2016 Mar;37(3):3823-30. doi: 10.1007/s13277-015-4213-5. Epub 2015 Oct 16.

PMID:
26474589
19.

Association between the overexpression of PBOV1 and the prognosis of patients with hepatocellular carcinoma.

Xue C, Zhong Z, Ye S, Wang Y, Ye Q.

Oncol Lett. 2018 Sep;16(3):3401-3407. doi: 10.3892/ol.2018.9013. Epub 2018 Jun 25.

20.

Identification of LZAP as a new candidate tumor suppressor in hepatocellular carcinoma.

Zhao JJ, Pan K, Li JJ, Chen YB, Chen JG, Lv L, Wang DD, Pan QZ, Chen MS, Xia JC.

PLoS One. 2011;6(10):e26608. doi: 10.1371/journal.pone.0026608. Epub 2011 Oct 19.

Supplemental Content

Support Center